Doctor, I noticed you opted for suture-based control when addressing bleeding in this high-risk patient. In many cases, especially involving patients with comorbidities or friable tissue, traditional methods like suturing can be time-consuming, technically demanding, and may cause additional tissue trauma.
In fact, retrospective data shows that over 30% of lung resection patients present with three or more comorbidities.¹ These patients often have compromised coagulation profiles, making reliable hemostasis more difficult and increasing the risk of postoperative bleeding, transfusion-related complications, and procedural inefficiencies.

I’d like to introduce you to VISTASEAL™, a fibrin sealant composed of human thrombin and fibrinogen, which forms a rapid, adherent, and durable clot forms a rapid, adherent, and durable clot on targeted tissue regardless of the patient’s coagulation profile.²⁻⁴ Unlike suturing, which requires tissue integrity and manual precision, VISTASEAL™ conforms to the tissue surface and provides immediate hemostasis with minimal manipulation.

Operationally, VISTASEAL™ is fast to set up with pre-filled syringes and no warming required, allowing you to address bleeding quickly and confidently.⁵ The flexible dual applicator also provides enhanced access to difficult anatomy—such as within the thoracic cavity—without needing to re-position instruments or retract fragile structures.

Given the clinical and procedural advantages, would you be open to evaluating VISTASEAL™ in your next few high-risk or anticoagulated patients to experience the difference in efficiency and performance compared to suturing?